Abstract
Background and aims
Diabetes mellitus is recognized as one of the major causes of end stage kidney disease. Bone Gla protein (BGP) is a vitamin K-dependent protein involved in bone mineralization and vascular calcifications (VC). Our goal was to characterize BGP and undercarboxylated BGP (ucBGP) in DM patients on HD, compared to HD patients without DM, and their association with vascular and bone disease.
Methods
387 HD patients from 18 dialysis centers in Italy. Associations of DM, levels of BGP, vitamin D and VC were evaluated. Time-to-event analysis for all-cause mortality was performed by the Kaplan–Meier.
Results
Patients with DM had lower levels of total BGP (139.00 vs. 202.50 mcg/L, p < 0.001), 25(OH)D (23.4 vs. 30.2 ng/ml, p < 0.001), and ucBGP (9.24 vs. 11.32 mcg/L, p = 0.022). In regression models, the geometric means of total BGP and ucBGP were 19% (p = 0.009) and 26% (p = 0.034) lower in diabetic patients. In univariate Cox regression analysis, DM patients had a higher risk of all-cause mortality (HR:1.83, 95% CI 1.13–2.96, p = 0.014). Adjustment for confounders confirmed the significant DM-mortality link. We included VC and warfarin into the Cox model, the DM-mortality link was no longer significant, suggesting a role of these risk factors as causal mediators leading to increased mortality in dialysis patients.
Conclusions
HD patients have an increased mortality risk associated with DM. Furthermore, we found an association between DM and decreased BGP levels. Although our study does not support the notion that BGP levels act as mediator in the DM-mortality link, to our knowledge this is the first study in HD patients suggesting a potential protective role of BGP in the bone, endocrine and vascular pathway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bergman A, Qureshi AR, Haarhaus M et al (2017) Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. J Nephrol 30(2):255–262
Torres PAU, Cohen-Solal M (2017) Evaluation of fracture risk in chronic kidney disease. J Nephrol 30(5):653–661
Neve A, Corrado A, Cantatore FP (2013) Osteocalcin: skeletal and extraskeletal effects. J Cell Physiol 228:1149–1153
Bacchetta J, Boutroy S, Guebre-Egziabher F et al (2009) The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transpl 24:3120–3125
Fusaro M, Gallieni M, Noale M et al (2014) The relationship between the Spine Deformity Index, biochemical parameters of bone metabolism and vascular calcifications: results from the Epidemiological VERtebral FRACtures iTalian Study (EVERFRACT) in dialysis patients. Clin Chem Lab Med 52:1595–1603
Fusaro M. Gallieni M, Rebora P et al (2016) Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients. J Nephrol 29:419–426
Shearer MJ (2000) Role of vitamin K and GLA proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 3:433–438
Fusaro M, Noale M, Viola V et al (2012) Vitamin K, vertebral fractures, vascular calcifications, and mortality: vitamin K Italian (VIKI) dialysis study. J Bone Miner Res 27:2271–2278
Witteman JC, Grobbee DE, Valkenburg HA et al (1994) J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet 343:504–507
Cranenburg EC, Vermeer C, Koos R et al (2008) The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 45:427–436
Kraemer HC, Stice E, Kazdin A et al (2001) How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry 158:848–856
Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270
Suksomboon N, Poolsup N, Ko HDKK (2017) Effect of vitamin K supplementation on insulin sensitivity: a meta-analysis. Diabetes, Metabolic Syndr Obes Targets Ther 10:169–177
Hussein AG, Mohamed RH, Shalaby SM, Abd El Motteleb DM (2018) Vitamin K2 alleviates type 2 diabetes in rats by induction of osteocalcin gene expression. Nutrition 47:33–38
Choi HJ, Yu J, Choi H et al (2011) Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes Care 34:e147
Luo XH, Zhao LL, Yuan LQ, Wang M, Xie H, Liao EY (2009) Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification. J Bone Miner Res 24:1461–1468
Confavreux CB, Szulc P, Casey R et al (2013) Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort. J Clin Endocrinol Metab 98:1084–1092
Bendix EF, Johansen E, Ringgaard T, Wolder M, Starup-Linde J (2018) Diabetes and abdominal aortic calcification—a systematic review. Curr Osteoporos Rep 16:42–57
Parker BD, Ix JH, Cranenburg EC et al (2009) Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study. Nephrol Dial Transpl 24:2095–2101
Fusaro M, Tripepi G, Noale M et al (2015) Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. Curr Vasc Pharmacol 13:248–258
Nakashima A, Yokoyama K, Yokoo T, Urashima M (2016) Role of vitamin D in diabetes mellitus and chronic kidney disease. World J Diabetes 7:89–100
Fusaro M, Giannini S, Gallieni M et al (2016) Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increased levels of vitamin K dependent proteins. Endocrine 51:333–341
Acknowledgements
We thank the VIKI Study Investigators, who provided patient clinical care and collected clinical data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This was an observational study conducted at 18 dialysis centers in Italy. All the local ethics committees approved the study, which was conducted according to the regulations in force related to observational studies. Approval dates ranged from July 14, 2008 to October 26, 2009. Patient enrollment took place between November 2008 and November 2009, and follow-up to assess vital status was performed in December 2011.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fusaro, M., Gallieni, M., Aghi, A. et al. Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. J Nephrol 32, 635–643 (2019). https://doi.org/10.1007/s40620-019-00595-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-019-00595-1